We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Im not too disappointed by the RNS. I think its more important to show the finances are under firm control than to throw about needless dividend payments,. I am surprised at the number of sells but hopefully the buying will increase as people see the sales improvements in the ST range and the new hair removal products start to generate additional income.
(Alliance News) - InnovaDerma PLC on Tuesday posted a narrowed loss for the first half of its financial year, helped by strong sales from its Skinny Tan self-tanning brand.
Shares in InnovaDerma were down 2.6% at 75.00 pence in London in late morning trading.
The beauty, personal care, and life science products firm reported a GBP347,501 pretax loss for the six months ended December 31, narrowed from a GBP422,311 loss the previous year as revenue climbed 31% to GBP5.1 million from GBP3.9 million.
"Skinny Tan has performed well in the period under review and revenue was up 40% compared to the same period last year. This has been driven by the rollout into Boots, continued support from Superdrug and exceptional popularity of Wonder Serum and the Choc range," Innovaderma said.
It further added that "Skinny Tan is very well-positioned for the tanning season in the second half of the year".
Sales of its Prolong device, designed to prevent premature ejaculation, were up 71% year-on-year, with direct-to-customer sales higher thanks to "online 'influencers', predominantly in the US". However, "growth comes from a low base". Prolong is one of InnovaDerma's Life Sciences brands.
Trading in the second half of the year has aligned with InnovaDerma's expectations, with trading in the first seven weeks up 17% year-on-year.
Executive Chair Joe Bayer said: "Trading since period end has remained positive, and we have in place new product launches across our topical brands and will continue to build on our successes in geographical markets outside the UK. We believe we are well-positioned but remain mindful of the challenging retail sector. The board looks forward to further growth in the second half and beyond."
On Monday, InnovDerma launched its new hair removal brand, Nuthing, which will be stocked in all Superdrug stores starting March 11 and will be sold online through the company's direct-to-consumer platform.
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.